Currency In USD
| Previous Close | 11.39 |
| Open | 11.36 |
| Day High | 11.36 |
| Day Low | 11.07 |
| 52-Week High | 15.04 |
| 52-Week Low | 8.01 |
| Volume | 82,600 |
| Average Volume | 1.09M |
| Market Cap | 660.91M |
| PE | 11.89 |
| EPS | 0.94 |
| Moving Average 50 Days | 11.46 |
| Moving Average 200 Days | 10.63 |
| Change | -0.21 |
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
GlobeNewswire Inc.
Mar 05, 2026 12:30 PM GMT
CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report c
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
GlobeNewswire Inc.
Feb 25, 2026 12:30 PM GMT
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Z